Samsung Biologics
Samsung Biologics · Bio CDMO
01Wall Street Consensus
02Earnings Results
Key Takeaways
- 1Q26 revenue ₩1.257T (+25.8% YoY) — quarterly record high
- Operating profit ₩580.7B (+35% YoY, OPM 46.2%)
- Net income ₩469.2B (+41.6% YoY)
- Plants 1-4 high utilization + Plant 5 gradual ramp-up
- Debt ratio 51.4% — solid balance sheet
Key Checkpoints
- 01Plant capacity utilization rate — Plants 1-4 combined utilization and customer fill rate
- 02Plant 5 construction progress — on-track for 2027 completion adding 240KL capacity
- 03New contract wins — deal pipeline and average contract value trend
- 04Operating margin — target 35%+ on operational leverage and premium pricing
- 05Customer diversification — reducing dependency on top-3 clients
- 06mRNA/ADC (antibody-drug conjugate) CDMO capability development
Upside Catalysts
- Global #1 CDMO capacity: 620KL total (Plants 1-4) — unmatched scale advantage
- Plant 5 (240KL): will cement dominance with 860KL total capacity by 2027
- Biosimilar wave: patent expirations for Humira, Keytruda, Opdivo driving CDMO demand surge
- GLP-1 biologics manufacturing: obesity drug boom creating new CDMO opportunities
- Defensive sector: healthcare/pharma relatively insulated from Iran conflict macro impact
Risk Factors
- Capacity risk: Plant 5 construction delay could limit 2027-2028 growth trajectory
- Competition: Lonza, WuXi Biologics, Fujifilm expanding CDMO capacity globally
- Regulatory: FDA inspection outcomes can impact client confidence and contract wins
- KOSPI macro: -4.37% crash creating risk-off environment for large-cap Korean biotech
- Currency: USD/KRW 1,508 — most contracts USD-denominated, but cost base is KRW
1Final Verdict
Samsung Biologics is the world's #1 biopharmaceutical CDMO by capacity with 620KL across Plants 1-4, and Plant 5 (240KL) under construction for 2027 completion. Consensus EPS ₩18,000, Revenue ₩1.2T.
The company sits at the intersection of two powerful trends: the biosimilar patent cliff (Humira, Keytruda, Opdivo) driving massive CDMO demand, and the GLP-1 obesity drug boom requiring biologics manufacturing scale that only Samsung Biologics can provide.
As a healthcare name, Samsung Biologics offers defensive positioning amid the Iran war-driven KOSPI selloff. USD-denominated contracts with KRW cost base provide a natural margin tailwind at USD/KRW 1,508.
2CDMO Market & Capacity
Capacity Leadership:
- Plants 1-4: 620KL total bioreactor capacity
- Plant 5: 240KL under construction, completion 2027
- Total at completion: 860KL — larger than Lonza + WuXi combined
- Utilization: 85-90% across existing plants
Contract Pipeline:
- Biosimilar manufacturing: patent cliff driving record RFP volume
- GLP-1/obesity biologics: emerging opportunity from Lilly, Novo, and others
- mRNA capability: building platform for next-gen vaccine/therapeutic manufacturing
- ADC (antibody-drug conjugate): expanding into high-growth oncology segment
Competitive Advantages:
- Scale: largest single-site CDMO globally (Songdo, Korea)
- Speed: fastest facility construction timelines in industry
- Quality: FDA, EMA, PMDA approved — global regulatory track record
- Samsung brand: multinational pharma companies trust Samsung reliability
SEPS 서프라이즈 히스토리
분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출
컨센서스 대비 실제 EPS/매출 서프라이즈 (%)